Most available data on the involvement of p53 in rodent carcinogenesis are based on results of the end point of chemically or virally induced carcinogenesis, i.e., tumors. To investigate the role of altered p53 expression in early stages of rodent hepatocarcinogenesis in a systematic way, we treated male Wistar rats for 6 wk, for 13 wk, and for 6 wk followed by a 7-wk recovery period with chemicals classified as genotoxic (200 ppm acetylaminofluorene [AAF], 100 ppm N-nitrosomorpholine [MMN], 200 ppm ben-zo(a)pyrene), as tumor promoters and carcinogenic in experimental animals (5 ppm ethinylestradiol, 500 ppm phenobarbitone, 3,000 ppm clofibric acid), as carcinogenic in animal experiments (600 ppm thioacetamide), as noncarcinogenic (200 ppm thyroxine), and as tumor promoters in experimental animals (20,000 ppm tryptophan, 120,000 ppm fructose). Immunohistochemical assessment of altered p53 expression on liver sections with polyclonal serum (CM5) resulted in positive staining in 17/21 benzo(a)pyrene-, 1/18 thioacetamide-, 2/21 clofibric acid-, 2/21 phenobarbitone-, 7/19 ethinylestradiol-, 1/21 tryptophan-, 3/19 thyroxine-, and 1/21 fructose-treated rats and in 2/19 controls. These data support earlier results obtained from analogous investigations with a high incidence of altered p53 expression after NNM and AAF treatment. Thus, altered p53 expression appears to be an early and frequent event in rodent carcinogenesis induced by genotoxic chemicals in contrast to most epigenetically acting chemicals.
1. Ashby J and Payton D (1995). Chemicals for evaluating the sensitivity and specificity of reduced/transgenic rodent cancer bioassay protocols. Mutat. Res.331: 27.
2.
2. Bennett WP, Colby TV, Travis WD, Borkowski A, Jones RT, Lane DP, Metcalf RA, Samet JM, Takeshima Y, Gu JR, Vahakangas KH, Soini Y, Paakko P, Welsh JA, Trump BF, and Harris CC (1993). p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res.. 53: 4817–4822.
3.
3. Caamano J, Ruggeri BA, and Klein-Szanto AJP (1992). A catalog of p53 alterations in selected human and laboratory animal neoplasms. In: Comparative Molecular Carcinogenesis, AJP Klein-Szanto (ed). Wiley-Liss, New York, pp. 331–355.
4.
4. Curtis CC (1995). Deichmann lecture–p53 tumor suppressor gene: At the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment. Toxicol. Leu.82/83: 1–7.
5.
5. Donehower LA and Bradley A (1993). The tumor suppressor p53. Biochim. Biophys. Acta1155: 181–205.
6.
6. Enzmann H, Ohlhauser D, Dettler T, and Bannasch P (1989). Enhancement of hepatocarcinogenesis in rats by dietary fructose. Carcinogenesis. 10: 1247–1252.
7.
7. Flamini G, Curigliano G, Ratto C, Astone A, Ferretti G, Nucera P, Sofo L, Sgambato A, Boninsegna A, Crucitti F, and Cittadini A (1996). Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer–An immunohistochemical analysis. Eur. J. Cancer32A: 802–806.
8.
8. Greenblatt MS, Bennett M, Hollstein M, and Harris CC (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res.. 54: 4855–4878.
9.
9. Hadjiolov N, Bitsch A, and Neumann HG (1995). Early initiating and promoting effects in 2-AAF-induced rat liver carcinogenesis: An immunohistochemical study. Cancer Leu.. 98: 39–46.
10.
10. Harris CC (1996). p53 tumor suppressor gene: From the basic research laboratory to the clinic–an all abridged historical perspective. Carcinogenesis. 17: 1187–1198.
11.
11. Harris CC and Hollstein MC (1993). Clinical implications of the p53 tumor suppressor gene. N. Engl. J. Med.. 18: 1318–1327.
12.
12. Ho YS, Cheng HT, Wang YJ, and Lin JK (1995). p53 gene mutational spectra in hepatocellular carcinomas induced by 2-acetylam-inofluorene and N-nitroso-2-acetyaminofluorene in rats. Mol. Car-cinog.. 13: 182–190.
13.
13. Hollstein M, Sidransky D, Vogelstein B, and Harris CC (1991). p53 mutations in human cancer. Science. 253: 49–53.
14.
14. Hollstein MC, Soussi T, Thomas G, von Brevern MC, and Bartsch H (1997). p53 gene alterations in human tumors: Perspectives for cancer control. Recent Results Cancer Res.. 143: 369–389.
15.
15. International Agency for Research on Cancer (1974). Some antithyroid and related substances. Nitrofurans and industrial chemicals. /ARC Monogr. Eval. Carcinog. Risk Chem. Hum.. 7: 77–83.
16.
16. International Agency for Research on Cancer (1976). Some miscellaneous pharmaceutical substances. IARC Monogr. Eval. Carcinog. Risk Chem. Hum.. 13: 157–181.
17.
17. International Agency for Research on Cancer (1979). Sex hormones (II). IARC Monogr. Eval. Carcinog. Risk Chem. Hum.. 21: 233–255.
18.
18. International Agency for Research on Cancer (1980). Some pharmaceutical drugs. IARC Monogr. Eval. Carcinog. Risk Chem. Hum.. 24: 39–58.
19.
19. International Agency for Research on Cancer (1983). Polynuclear aromatic compounds, Part 1. Chemical, environmental and experimental data. IARC Monogr. Eval. Carcinog. Risk Chem. Hum.. 32: 211–224.
20.
20. Ko LJ and Prives C (1996). p53: Puzzle and paradigm. Genes Dev.. 10: 1054–1072.
21.
21. Levine A (1993). The tumor suppressor genes. Annu. Rev. Biochem.. 62: 623–651.
22.
22. Masui T, Nakanishi H, Inada K, Imai T, Mizoguchi Y, Yada H, Futakuchi M, Shirai X and Tatematsu M (1997). Highly metastatic hepatocellular carcinomas induced in male F344 rats treated with N-nitrosomorpholine in combination with other hepatocarcinogens show a high incidence of p53 gene mutations along with altered mRNA expression of tumor-related genes. Cancer Lett.. 112: 33–45.
23.
23. Mayol X, Neal GE, Davies R, Romero A, and Domingo J (1992). Ethinylestradiol-induced cell proliferation in rat liver. Involvement of specific populations of hepatocytes. Carcinogenesis. 13: 2381–2388.
24.
24. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane DP, and Barnes DM (1992). Expression of human p53 in bacteria: Application to the analysis of p53 expression in human tumors. J. Cell Sci.. 101: 183–189.
25.
25. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, and Zambetti G (1996). Cytoplasmic sequestration of wildtype p53 protein impairs the G, checkpoint after DNA damage. Mol. Cell. Biol.. 16: 1126–1137.
26.
26. Oren M (1994). Relationship of p53 to the control of apoptotic cell death. Semin. Cancer Biol.. 5: 221–227.
27.
27. Oren M and Prives C (1996). p53: Upstream, downstream and off stream. Review of the 8th p53 workshop (Dundee, July 5-9, 1996). Biochim. Biophys. Acta. 1288: 13–19.
28.
28. Ostermeyer AG, Runko E, Winkfield B, Ahn B, and Moll U (1996). Cytoplasmically sequestered wildtype p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal eptide. Proc. Natl. Acad. Sci. USA. 93: 15190–15194.
29.
29. Prives C (1994). How loops, β sheets and helices help us to understand p53. Cell78: 543–546.
30.
30. Ruggeri B, DiRado M, Zhang SY, Bauer B, Goodrow T, and Klein-Szanto AJP (1993). Benzo(a)pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc. Natl. Acad. Sci. USA. 90: 1013–1017.
31.
31. Scpehrina B, Paz IB, Dasgupta G, and Mohmand J (1996). Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J. Biol. Chem.. 271: 15084–15090.
32.
32. Soussi T, Legros Y, Lubin R, Orym K, and Schlichtholz B (1994). Multifactorial analysis of p53 alterations in human cancer: A review. Int. J. Cancer. 57: 1–9.
33.
33. Spiegel A and Gonnert R (1961). Neue Kafige fiir Mause und Ratten. Z. Versuchstierkd.. 1: 38–46.
34.
34. Sun XF, Carstensen JM, Zhang H, Satl O, Wingren S, Hatschek T, and Nordenskjold B (1992). Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adeno-carcinoma. Lancet. 340: 1369–1373.
35.
35. Tanaka K, Smith PF, Stromberg PC, Eydelloth RS, Herold EG, Grossman SJ, Frank JD, Hertzog PR, Soper K, and Keenan KP (1992). Studies of early hepatocellular proliferation and peroxisomal proliferation in Sprague-Dawley rats treated with tumorigenic doses of clofibrate. Toxicol. Appl. Pharmacol.. 116: 71–77.
36.
36. Tennant RW, French JE, and Spalding W (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect.. 103: 942–946.
37.
37. Trivers GE, De Benedetti VMG, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, and Harris CC (1996). Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin. Cancer Res.. 2: 1767–1775.
38.
38. Vancutsem PM, Lazarus P, and Williams GM (1994). Frequent and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res.. 54: 3864–3867.
39.
39. Williams GM and Weisburger JH (1991). Chemical carcinogenesis. In: Toxicology: The Basic Science of Poisons, MO Amdur, J Doull, and CD Klaassen (eds). Pergamon, Oxford, England, pp. 127–200.
40.
40. Wirnitzer U, Enzmann H, Rosenbruch M, and Bomhard EM (1995). Accumulation of p53 protein in chemically induced oval cells during early stages of rodent hepatocarcinogenesis. Carcinogenesis. 16: 697–701.
41.
41. Yager JD, Zurlo J, Sewall CH, Lucier GW, and He H (1994). Growth stimulation followed by growth inhibition in livers of female rats treated wim ethinylestradiol. Carcinogenesis. 15: 2117–2123.
